Summary of Presentations from the Celgene-Sponsored Satellite Symposium, held at the 19th EHA Congress, Milan, Italy, on 12th June 2014
Chairperson: Pier Luigi Zinzani1
Speakers: Bruce Cheson,2 Andrew Zelenetz,3 Martin Dreyling,4 Bertrand Coiffier5
1. S. Orsola-Malpighi Hospital, Bologna, Italy
2. Georgetown University Hospital, Washington, DC, USA
3. Memorial Sloan-Kettering Cancer Center, New York City, New York, USA
4. Ludwig Maximilians-University, Munich, Germany
5. Hospices Civils of Lyon, and Claude Bernard University, Lyon, France
Disclosure: Bruce Cheson, who has received fees from Celgene, Astra-Zeneca, Roche-Genentech, Pharmacyclics, Gilead, and Medimmune for consultancy services and/or research support, could not attend the Congress so his presentation was given by Andrew Zelenetz. Andrew Zelenetz has received fees from Genentech/Roche, Gilead, Sanofi-Aventis, Hospira, Dr Reddy Laboratories, Jansen/ Pharmacyclics, Lymphoma Research Foundation, Cancer Genetics Institute, and BMS for consultancy services, advisory boards, research support, and/or clinical trials. Martin Dreyling has received fees from Celgene, Janssen, Mundipharma, Pfizer and Roche, Bayer, and Gilead for research support, speaker honoraria and/or advisory boards. Bertrand Coiffier has acted as Consultant for Celgene, who also support LYSARC for clinical trials and is a member of Data and Safety Monitoring Board for the Millennium study.
Acknowledgements: Writing assistance was provided by Dr Juliet Bell, associated with ApotheCom ScopeMedical.
Support: Medical writing assistance was funded by Celgene. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Celgene.
Citation: EMJ Hema. 2014;1:40-49.
Prof Zelenetz opened the symposium on the evolving front-line treatment options for follicular lymphoma (FL) and discussed the potential of novel agents to replace chemotherapy. Prof Zelenetz presented the heterogeneity of diffuse large B cell non-Hodgkin’s lymphoma (DLBCL) with regard to the diagnosis and subtypes of DLBCL to describe the specificity of new agents towards certain DLBCL subgroups, whilst Prof Dreyling spoke about the current diagnosis and treatment pathways for mantle cell lymphoma (MCL), and briefly described recent trial results. The final presenter, Prof Coiffier, discussed the lack of efficacy of front-line chemotherapy regimens for peripheral T cell lymphoma (PTCL), and highlighted potential new treatments based upon CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone). He then addressed the use of transplantation for first-line and refractory disease, and called for research to optimise therapy using existing agents.